Redhill Biopharma Accounts Payable

As of the most recent data (December 2025), RDHL shows a accounts payable of $6.4M. That compares with $7.9M in the prior-year period — down 18.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RDHL's accounts payable is now $6.4M (was $7.9M) — a 18.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Redhill Biopharma is outperforming or lagging.

Tracking RDHL's accounts payable over time shows whether Redhill Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $6.4M That compares with $7.9M in the prior-year period — down 18.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Redhill Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $6.4M) with ownership activity and broader fundamentals.

Redhill Biopharma's accounts payable is $6.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.